NCT06132113 - DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

July 6, 2026

Study Completion Date

August 10, 2026

Conditions

Neuroendocrine Neoplasms

Interventions

DRUG

BI 764532

DRUG

Carboplatin

Standard of care

DRUG

Etoposide

Standard of care

DRUG

Cisplatin

Standard of care

Trial Locations (21)

1200

RECRUITING

Brussels - UNIV Saint-Luc, Brussels

2650

RECRUITING

Edegem - UNIV UZ Antwerpen, Edegem

13273

RECRUITING

INS Paoli-Calmettes, Marseille

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28046

RECRUITING

Hospital La Paz, Madrid

30322

RECRUITING

Winship Cancer Institute, Atlanta

33136

RECRUITING

University of Miami, Miami

60611

NOT_YET_RECRUITING

Northwestern University, Chicago

69500

NOT_YET_RECRUITING

HOP Louis Pradel, Bron

72076

RECRUITING

Universitätsklinikum Tübingen, Tübingen

81377

NOT_YET_RECRUITING

Klinikum der Universität München AÖR, München

07601

NOT_YET_RECRUITING

John Theurer Cancer Center, Hackensack

464-8681

RECRUITING

Aichi Cancer Center Hospital, Aichi, Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East, Chiba, Kashiwa

541-8567

RECRUITING

Osaka International Cancer Institute, Osaka, Osaka

104-0045

RECRUITING

National Cancer Center Hospital, Tokyo, Chuo-ku

9713 GZ

RECRUITING

Universitair Medisch Centrum Groningen, Groningen

08035

RECRUITING

Hospital Vall d'Hebron, Barcelona

413 46

RECRUITING

Sahlgrenska Universitetsjukhuset, Gothenburg

751 85

NOT_YET_RECRUITING

Akademiska hospital, Uppsala